Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/23/2887684/0/en/Replimune-to-Present-at-the-2024-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/05/16/2883354/0/en/Replimune-Reports-Fiscal-Fourth-Quarter-and-Year-Ended-2024-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com/news-release/2024/04/07/2858850/0/en/Interim-Results-from-the-ARTACUS-Clinical-Trial-of-RP1-Monotherapy-in-Solid-Organ-and-Hematopoietic-Cell-Transplant-Recipients-with-Skin-Cancers-Presented-During-Oral-Presentation-.html
https://www.globenewswire.com//news-release/2024/03/06/2841384/0/en/Replimune-to-Present-at-the-American-Association-for-Cancer-Research-Annual-Meeting-2024.html
https://www.globenewswire.com//news-release/2024/02/08/2825950/0/en/Replimune-Reports-Fiscal-Third-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html
https://www.fiercebiotech.com/biotech/replimune-shares-halve-skin-cancer-drug-fails-cerpass-phase-2
https://www.globenewswire.com//news-release/2023/11/07/2775019/0/en/Replimune-Reports-Fiscal-Second-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com//news-release/2023/11/03/2773500/0/en/Replimune-Presents-Updated-Interim-Results-from-the-ARTACUS-Clinical-Trial-of-RP1-Monotherapy-in-Solid-Organ-and-Hematopoietic-Cell-Transplant-Recipients-with-Skin-Cancers-During-O.html
https://www.globenewswire.com//news-release/2023/09/19/2746007/0/en/Replimune-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com//news-release/2023/09/19/2745558/0/en/Replimune-Announces-Appointment-of-Emily-Hill-as-Chief-Financial-Officer.html